Theophylline inhibits the late asthmatic response to nighttime antigen challenge in patients with mild atopic asthma.
BACKGROUND
Inhaled antigen at night causes a more pronounced late asthmatic response (LAR) when compared with daytime challenges. Chronopharmacology with controlled-release theophylline given in the evening leads to a peak serum theophylline concentration (STC) in early morning which coincides with LAR that follows an evening challenge.


OBJECTIVE
To evaluate the effect of controlled-release theophylline given with the evening meal on the immediate asthmatic response (IAR) and LAR following nighttime antigen challenge in patients with mild atopic asthma.


METHODS
To qualify, subjects underwent antigen bronchoprovocation by graded nebulization until the IAR (fall in FEV1 of > or =20%) occurred; spirometry was then measured hourly for 8 hours to establish the presence of LAR (fall in FEV1 > or =15%). After 2 weeks of randomized, double-blind crossover treatment with either theophylline (target STC of 10 to 15 mg/L, (56 to 83 micromol/L)) or placebo, inhaled antigen challenge was performed at 10 PM in each subject. FEV1 values were measured immediately and then hourly for 8 hours following antigen challenge.


RESULTS
Twelve subjects completed the study. During the placebo phase, the maximal fall in FEV1 during LAR was 39 +/- 3% (mean +/- SEM) compared with 31 +/- 4% fall during theophylline treatment phase (P = .01). A reduction in LAR occurred despite higher dose (P <.05) of inhaled antigen during theophylline phase, which would have been expected to result in a more pronounced LAR. Serum theophylline concentration at 8 AM on the day following antigen challenge was 9.6 +/- 1.1 mg/L (53 +/- 6 micromol/L).


CONCLUSIONS
Nocturnal administration of controlled-release theophylline increases the tolerance to inhaled antigen and reduces severity of LAR. Because the LAR is linked to airway inflammation, these data support the possibility of antiinflammatory effects associated with theophylline use.
Department of Medicine, University of Wisconsin-Madison Medical School, USA.
N N
NN
Jarjour
P G
PG
Lacouture
W W
WW
Busse
D000328:Adult; D001249:Asthma / Q000188:drug therapy / Q000276:immunology* / Q000503:physiopathology*; D001985:Bronchial Provocation Tests; D002940:Circadian Rhythm; D003692:Delayed-Action Preparations; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000276:immunology*; D008297:Male; D013806:Theophylline / Q000494:pharmacology* / Q000627:therapeutic use
D003692:Delayed-Action Preparations; D013806:Theophylline